MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) (“the Company”), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces registration and connection details for its SENS-601 Program Day, to be held on September 22, 2026. As previously announced, the SENS-601 Program Day will be dedicated to the Company's SENS-601 program, i